A probabilistic knowledge graph for target identification
Fig 6
In-vitro validation of the target candidates predicted by Progeni for colorectal cancer (CRC).
(A), CCK-8 assays of the MC38 cells with shRNA knockdown after 36h culture. (B)-(D), Survival curves of the primary colorectal cancer patients from The Cancer Genome Atlas (TCGA) with high or low expression of ADCY5 (n = 264, (B)), ADRA2A (n = 264, (C)), and EEF2 (n = 264, (D)), respectively. The patients with the 30% highest gene expression were defined as “High,” while the lowest 30% were defined as “Low.” (E)-(F), CCK-8 assays of the MC38 (C) and CT26 (D) cells after 48h treatment with the ADRA2A inhibitor phentolamine, whose molecular structures and half maximal inhibitory concentration (IC50) values are also shown.